Alvotech Commences Public Offering & Private Placement for $125M

Alvotech announced the commencement of an underwritten public offering of its ordinary shares. Concurrently, the company expects to conduct a private placement with certain investors at the public offering price. Alvotech anticipates raising approximately $125 million in gross proceeds from both offerings. The funds are intended to support the continued development of its biosimilar assets, working capital, and general corporate purposes, including potential acquisitions and debt repayment.